Wills, Anne-Marie
,
Li, Ruosha
Pérez, Adriana
Ren, Xuehan
Boyd, James
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (U10 NS053369, U10 NS044501, U01NS043127)
Article History
Received: 3 March 2017
Revised: 16 June 2017
Accepted: 29 June 2017
First Online: 15 July 2017
Compliance with ethical standards
:
: Dr. Wills has received research support from the NIH, the MDA, ALSA, has consulting agreements with Accordant, a CVS/Caremark disease management company and with Sage Bionetworks and has participated in clinical trials funded by Merck, Acorda and Pfizer. Dr. Pérez reports NIH grants and Texas Department of State and Human Services grants. Ruosha Li and Xuehan Ren report grants from the NIH. Dr. Boyd served as a consultant and/or scientific advisor for AbbVie, Auspex, Teva, Lundbeck, Chronos Therapeutics, Neurocrine, and Medical Education Resources. He has received research support from the Michael J. Fox Foundation for Parkinson Research, NIH/NINDS, Auspex, Biotie, CHDI Foundation, Vaccinex, Teva, AbbVie, NeuroDerm, and Roche.
: The authors declare no conflicts of interest.